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Abstract:
Objective: There are concerns with increased prices and drug shortages for pertinent medicines and 
personal protective equipment (PPE) to prevent and treat COVID-19 enhanced by misinformation. 
Community pharmacists and drug stores play a significant role in disease management in Bangladesh due 
to high co-payments. Consequently, a need to review prices and availability in the pandemic. Materials 
and Methods: Multiple approach involving a review and questionnaire among pharmacies and stores 
early March to end May 2020. Results and Discussion: 170 pharmacies and drug stores took part, giving 
a response rate of 63.9%. Encouragingly, no change in utilization of antimalarial medicines in 51.2% 
of stores despite global endorsements. However, increased utilisation of antibiotics (70.6%), analgesics 
(97.6%), vitamins (90.6%) and PPE (over 95%). Encouragingly, increases in purchasing of PPE. No 
increase in prices among 50% of the stores for antimalarials, with a similar situation for antibiotics 
(65.3%), analgesics (54.7%), and vitamins (51.8%). However, price increases typically for PPE (over 
90% of stores). Shortages also seen for medicines and PPE, again greater for PPE. Conclusions: The 
pandemic has impacted on the supply and prices of medicines and PPE in Bangladesh. Key stakeholder 
groups can play a role addressing misinformation, with enhanced local production helping address future 
shortages and prices.
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1. Introduction/ Background
1.1 General and Bangladesh
The coronavirus disease 2019 (COVID-19) 
pandemic was first identified in Wuhan, China, 
during December 2019, and by 19 June 2020, 
there were 8.385 million cases and over 450,000 
deaths worldwide giving a case fatality ratio (CFR) 
among confirmed cases of 5.37%1-3. This included 
over 541,000 confirmed cases in the WHO South 
East Asian Region, including Bangladesh, with 
over 16,300 deaths giving a CFR 3.02%1. The first 
reported cases for COVID-19 in Bangladesh were in 
early March 20204-6, and by 15 June 2020, there were 
over 90,600 cases with just over 1,200 deaths giving 
a CFR of 1.33%7,8. However, there are concerns with 
appreciable under-reporting of cases due to limited 
testing capabilities9-13. For instance, by 24 March 
2020 in Bangladesh, the Institute of Epidemiology, 
Disease Control and Research (IEDCR) laboratory 
had only tested 675 samples with 565 new tests 
continues others authors page S 37
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undertaken since 13 March 20205.
There are also concerns that due to a lack of 
resources and personnel, along with high levels of 
both infectious and non-infectious disease, that 
COVID-19 could overwhelm Bangladesh11,14-21. This 
includes high prevalence rates of coronary vascular 
disease (CVD) and diabetes19,20, including both 
macro- and microvascular complications16,18,20,22,23, 
as well as hypertension17,18,24,25. Concerns include 
a lack of intensive care unit (ICU) beds among 
public hospitals in Bangladesh to treat patients 
with severe COVID-194,12,15,26. Medicine costs are 
already a concern in Bangladesh as they account for 
an appreciable proportion of direct medical costs 
(83.5%) for treating patients with type 2 diabetes 
(T2DM) in the community, which is typically out-of-
pocket27. This is a concern as Kasonde et al. (2019) 
recently ascertained that several purchased medicines 
to manage non-communicable diseases (NCDs) 
in Bangladesh were expensive by international 
standards, with the least affordable being bisoprolol 
(for hypertension), metformin and atorvastatin, 
adding to concerns with affordability to treat family 
members with T2DM28. 
We are aware of ongoing plans in Bangladesh to 
reduce the prevalence and burden of NCDs; however, 
there are concerns with their implementation29-32. 
There are also currently high rates of smoking in 
Bangladesh, up to 35% of the adult population, 
highest among the South East Asian countries11,33-35, 
adding to the cost and burden of NCDs35,36, which 
also needs to be addressed.
With respect to infectious diseases, there are concerns 
with high rates of antimicrobial resistance (AMR) in 
Bangladesh exacerbated by high rates of inappropriate 
prescribing and dispensing of antibiotics, including 
macrolides such as azithromycin37-42, which have 
resulted in a National Action Plan to try and address 
this43. Encouragingly for patients, prices of essential 
antibiotics in private pharmacies in Bangladesh, 
including model stores, were not much higher than 
international prices in a recent study by Rahman et 
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al. (2019), with only limited price increases between 
2003 and 201944. The increase in cases with dengue21, 
and the continued challenges with tuberculosis in 
Bangladesh, with patients typically seeking help from 
non-qualified practitioners before seeking help from 
qualified professionals, also needs addressing45-48. 
Encouragingly, whilst there are still cases of malaria 
in Bangladesh, co-ordinated activities have reduced 
these by more than 50% in 2016 versus 201049. 
Targeting and managing hotspots will help further 
reduce and eliminate malaria, which is the goal of 
the Government49,50. Pharmacies can also take part 
in immunization programs in Bangladesh, especially 
where there are bottlenecks51.   
1.2 Bangladesh Healthcare Systems Including 
Community Pharmacy and Drug Stores
Payment for health care provision in Bangladesh 
is typically out-of-pocket, with Bangladesh having 
one of the highest rates of catastrophic healthcare 
expenditures worldwide52. As a result, a significant 
number of households are forced to sell assets or 
borrow money to fund treatments when family 
members become ill52. COVID-19 will only add to 
these concerns. 
Consequently, retail drug stores, both licensed 
and unlicensed in equal numbers, are important in 
Bangladesh as they are often the principal source 
of healthcare for patients given their financial 
circumstances14,41,53. A key concern though has been 
a lack of formal counseling within stores unless 
pro-actively sought by patients53,54, with currently 
more than 80% of the population in Bangladesh 
preferentially seeking care from drug stores as well 
as untrained or poorly trained village doctors53. 
However, there have been recent steps to address 
concerns with the publication of standards for drug 
outlets55. Under this system, in a Model Pharmacy 
(Level I), the service should be provided, managed, 
or supervised by an A grade pharmacist, with B or 
C grade pharmaceutical personnel assisting with 
dispensing under supervision. In a Model Medicine 
Shop (Level II), the service should be performed at 
a minimum by a C graded professional55. However, 
unregulated drug shops are still seen as essential 
as excessive regulations adding to costs could 
potentially remove access to medicines for many of 
the population41.
1.3 Risk Factors and Approaches to Prevent and 
Treat COVID-19 - General
COVID-19 is transmitted from person to person 
principally through respiratory droplets56,57, with 
increased morbidity and mortality associated with 
several underlying health conditions including 
cardiovascular disease (CVD), hypertension, 
diabetes, chronic obstructive pulmonary disease 
(COPD), shortness of breath and smoking58-65. 
Ethnicity may also be important, with patients in 
the United Kingdom of Bangladesh origin having 
appreciably increased mortality from COVID-1966-69. 
There were concerns initially that renin-angiotensin 
inhibitors would enhance susceptibility to 
COVID-19, as well as increase its severity, leading to 
recommendations to stop these treatments, which is a 
concern in Bangladesh given current high prevalence 
rates of CVD, diabetes, and hypertension17,19,20,70. 
However encouragingly, recent studies have shown 
no such association71,72. 
Currently, there appears to be no cure for 
COVID-19; however, several medicines have been 
proposed and are undergoing trials73,74. There have 
been several published studies on chloroquine and 
hydroxychloroquine with or without azithromycin 
following initial studies in China75-78. However, 
there were concerns with the lack of comparisons 
in early studies and side-effects, including cardiac 
side-effects, with more recent studies documenting 
issues with their effectiveness as more data becomes 
available75,78-85. The study of Mehra et al. (2020) 
showed increased mortality; however, now retracted 
and subject to external auditing86,87. As a result of 
more recent studies, including the UK Recovery trial, 
the WHO has halted the hydroxychloroquine arm in 
the ongoing Solidarity Trial1,84. There have also been 
similar activities among European countries as well 
as with the National Institute of Health in the US88,89. 
Remdesivir has shown encouraging results following 
earlier concerns90,91, and triple antiviral therapy is 
also showing promise although patients numbers are 
small92. More recently, dexamethasone has improved 
outcomes in ventilated patients and those receiving 
oxygen93. However, further studies are needed before 
specific treatments can be robustly recommended, 
given the redaction of recent studies and concerns 
with study designs79,94,95. 
This lack of recommended treatments has resulted in 
companies and individuals exploiting the opportunity 
often with misinformation96-98. Misinformation 
and the endorsement of hydroxychloroquine 
by Governments and others99-104 has increased 
prices alongside hospitalizations and deaths from 
poisoning100,105-108. This is a concern in countries 
such as Bangladesh with potentially catastrophic 
consequences for families, especially if funds for 
other diseases are diverted towards purchasing 
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increasingly expensive unproven treatments. 
1.4 Activities by the Government and Others in 
Bangladesh to Reduce the Spread and Mortality 
due to COVID 19
The Government, WHO, and others have instigated 
a variety of financial and other measures to help 
prevent the spread of COVID 19 and reduce 
financial and socioeconomic consequences (Table 1). 
During this period, the WHO also issued guidance 
on misinformation by providing updates on ‘myth 
busters’109. 
Table 1: Activities Instigated to Help Prevent the 
Spread of COVID-19 in Bangladesh and Associated 
Financial Consequences. 
Sector Activities
Health/ prevention 
i n c l u d i n g 
shortages
•	 First week of March 2020 – The Government 
started to postpone/ cancel all mass 
gatherings11 
•	 March 15, 2020 The Government banned all 
flights coming from Europe except the United 
Kingdom; however, flights from Europe still 
landed11,110, with further bans on International 
travel introduced later11
•	 March 16, 2020 The Government imposed a 
14-day obligatory quarantine on all travelers 
entering Bangladesh11,111, and on March 19, 
the Government deployed the army to help 
supervise two quarantine facilities in Dhaka11,112
•	 March 16, 2020 The Government closed all 
educational institutes5 
•	 March 19, 2020 The Government instructed 
local administrations to ban political and 
religious rallies as well as social and cultural 
gatherings5
•	 March 23, 2020 The Government announced 
the closure of all public and private offices5
•	 March 25, 2020 The Government declared 
the enforcement of lockdown measures for 
10 days effective from March 26, which has 
been further extended4,11,113. However, there 
were concerns with the lack of coordination 
between different authorities reducing its 
impact, and in reality, social distancing is 
impractical in many over-crowded cities, 
especially among the slum areas11. In some 
areas, 10 to 16 families share one bathroom or 
toilet and no regular supply of water11,114
•	 June 12, 2020 The Government introduced 
the concept of risk zones for the prevention of 
COVID-19 into Red, Yellow, and Green zones 
based on prevailing risks. On 14 June 2020, 
11 red zones were declared in Chittagong City, 
and from 16 June 2020, all shops, including 
pharmacies, in the area must remain closed 
during this period. Other red zones included 
Kattuli, Khulshi, Chittagong Port, Halishahar 
and Patenga7,115
•	 Ongoing concerns with enough Personal 
Protective Equipment11; although gifts have 
helped to reduce concerns102 
Sector Activities
F i n a n c i a l / 
soc ioeconomic 
consequences
•	 March 18-2020 - The Government adopts the 
National Preparedness and Response Plan 
(NPRP) for COVID-19 in Bangladesh with a 
total cost of US$29.550 billion5 
•	 April 3-2020 - The World Bank fast tracks 
US$100million to support Government efforts 
to tackle COVID-19 in Bangladesh116 
•	 June 2020 - The International Monetary Fund 
approved a US$732 million disbursement 
package to Bangladesh to help further 
address the financial impact of the COVID-19 
pandemic including concerns with an 
appreciable reduction in income form garment 
manufacturing4,12,117
An ongoing concern are the unintended consequences 
of COVID-19 with clinics, and hospitals shut 
down due to fears of infection13. These include 
stigmatization of healthcare workers who have 
treated COVID-19 patients13,118, as well as an 
increase in mental health disorders enhanced by 
concerns with employment and available resources 
to purchase food with existing high poverty levels in 
Bangladesh13,119,120.
1.5 Role of Pharmacists and Others in Drug Stores 
in the Prevention and Management of COVID 19 
Including Unintended Consequences
Pharmacists and similar healthcare professionals 
in Bangladesh can prevent and manage patients 
with COVID-19 as well as help address unintended 
consequences121,122. This includes addressing issues 
of availability, access, and adherence to medicines in 
patients with chronic NCDs during the pandemic123-129. 
Potential activities also include giving guidance on 
prevention and possible treatments of COVID-19 
based on evidence rather than misinformation as well 
as reinforcing Government messages to prevent the 
spread of COVID-19, including purchasing personal 
protection equipment (PPE)122,130-133. Suggested 
activities also include appropriate referral of patients 
with more severe symptoms132. This is important as it 
can be difficult in practice to differentiate respiratory 
tract infections from COVID-19 in patients presenting 
with coughs and fever134.
Pharmacists and others could also offer online or 
phone counseling services for patients, promote 
the rational use of medicines, and potentially offer 
vaccination services130,135. However, this may require 
improved professionalism among pharmacists and 
store owners136-138. Pharmacists and others also 
need to balance demand and supply of medicines, 
which is essential in countries with high patient co-
payments and existing concerns with the availability 
of medicines in healthcare facilities126,139. 
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1.6 Study Objectives
Consequently, we believe there is a need in Bangladesh 
with its high rate of both infectious and communicable 
diseases, considerable concerns with over-crowding 
and sanitation, as well as catastrophic consequences 
for families when members become ill, to assess the 
impact of COVID-19 on the availability and prices 
of suggested medicines and other technologies to 
prevent and treat COVID-19 among pharmacies and 
drug stores. We have noted that previous research 
in Bangladesh showed limited increases in the 
prices of antibiotics over time, although there were 
concerns with the prices of some medicines to treat 
patients with NCDs28,44. However, we believe there 
are likely to be shortages of suggested medicines to 
treat COVID-19 in Bangladesh with considerable 
importing of raw materials potentially affecting 
medicine prices140. Consequently, we wished to assess 
the current situation to provide future guidance. 
We will not be assessing the influence of the 
various Government initiatives on the prevalence 
and mortality of COVID-19 in Bangladesh due to 
concerns with current low testing rates as well as 
evolving strategies such as risk zones (Table 1)8,141. 
However, we will be monitoring this in the future 
alongside unintended consequences given rising 
prevalence rates of COVID-19 in Bangladesh as 
lockdown measures ease, Bangladesh being one of 
the world’s most densely populated countries11,142 
and with existing high rates of both infectious and 
non-infectious diseases. 
2. Methodology
We undertook a multiple approach involving 
a narrative review of the current situation with 
COVID-19. This included a review of current 
prevalence rates and treatment approaches as well 
as the role of community pharmacists alongside 
issues of misinformation. This was combined with 
a comprehensive questionnaire survey among 
community pharmacies and drug stores in Bangladesh 
to assess the current situation regarding prices, 
availability, and usage patterns of carefully selected 
medicines potentially used in the management of 
COVID-19 as well as PPE. 
Convenient sampling was used, with snowballing 
used to collect most requested data through emails and 
other mechanisms with known contacts; otherwise, 
direct contact with pharmacy shop personnel for the 
remainder (cold calling). There was no sample size 
calculation as there was no previous data to base 
calculations upon. However, the intention was to 
undertake the research among an appreciable number 
of pharmacies and drug stores across Bangladesh as 
this was the first comprehensive study in this area 
worldwide, and we wanted to ensure good coverage.
Key questions to assess the patterns of demand, 
availability, and price changes of the selected 
medicines and equipment, as well as pharmacists 
potential future role to reduce misinformation, are 
contained in Box 1. The questions were open-ended 
without specific categories as there was no pre-
existing data to guide this, and they were provided 
as an Excel spreadsheet. Where possible, exact 
details were sought from the community pharmacists 
and store owners. Where this proved difficult, more 
general information was sought.
Box 1: Key Questions to Community Pharmacists 
and Drug Store Owners in Bangladesh Regarding 
Prevention and Treatment for COVID-19
•	 Geographic location (Region)
•	 What change in medicine purchasing patterns have you 
noticed from the beginning of March until the end of May 
2020 for antimalarials (hydroxychloroquine), antibiotics 
(e.g., azithromycin and co-amoxiclav), analgesics, and 
multivitamins/ immune boosters, based principally on invoices 
or other information sources were available. In addition, in 
some pharmacies, details regarding cold remedies and allergy 
medicines
•	 What changes in the prices of targeted medicines have you 
noticed from the beginning of March until end May 2020, e.g., 
for antimalarials, antibiotics, analgesics, and multivitamins 
(based on invoices or other information sources) as well as cold 
remedies/ allergy medicines (some pharmacies)
•	 Similarly, for PPE, e.g., face masks, hand sanitizers/ antiseptics, 
as well as thermometers (beginning of March until end May 
2020 - based on invoices or other information sources including 
impressions)
•	 What shortages/availability concerns have you noticed from 
the beginning of March until end May for pertinent medicines, 
vitamins, face masks, hand sanitizers and thermometers (based 
on stock levels or other information sources/ impressions)
•	 Any suggestions for addressing inappropriate self-medication 
for the future, including addressing misinformation from 
patients?
The Pharmacists/ drug store personnel were briefed 
on the objectives of the study with the option to 
participate or not, with confidentiality maintained 
throughout. Our hypothesis, based on findings in 
other countries, was that there would be shortages of 
antimalarial medicines and an appreciable increase 
in their prices, with a similar situation for antibiotics, 
vitamins, and hygiene equipment. In most situations, 
all pharmacies/ drug stores (170 stores) were 
included whilst in others (110 pharmacies/ drug 
stores), additional data was collected on antiseptics 
and medicines for common allergies/ colds.
We combined the data collected with the experience 
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of the co-authors regarding issues of health policy, 
health, pharmaceutical care, and self-purchasing 
in LMICs, to provide future direction, building 
on comments from the interviewees. We have 
successfully used this approach before to provide 
future direction143-148. The findings on the purchasing 
patterns, issues of shortages, and price changes will 
be compiled into tabular format. No formal statistical 
analysis was performed as it was envisaged that the 
level of detail would vary considerably by store.  
We did not systematically review publications for 
their quality using well-known scales such as the 
Newcastle-Ottawa scale as some quoted papers are in 
pre-publication format, and there are a considerable 
number of internets sources149. However, these were 
reviewed for appropriateness prior to inclusion. We 
also did not seek ethical approval, as this study did 
not involve patients. However, we sought approval 
from pharmacy managers and drug store owners 
before participation with interviewees given the 
opportunity to refuse. This is in line with previous 
studies undertaken by the co-authors in related areas, 
including policies to enhance the rational use of 
medicines and address issues of medicine shortages 
involving contact with academics, health authority 
personnel, and their advisers143,145,147,148,150,151.
3. Results
Overall, 170 pharmacies and drug stores took part in 
the survey (Table 2), giving a response rate of 63.9%.
Table 2: Details of Responses Among Pharmacy/ 
Drugs Stores Approached
Consolidated Interview 
Groups
How Many 
Pharmacies/ 
Stores 
Approached 
(N)
How 
Many 
Accepted 
to Take 
Part (N)
How 
Many 
Refused 
(N)
Group 1 58 26 32
Group 2
Personal 
communication 57 57 0
Cold Calling 95 53 42
Total 152 110 42
Group 3 34 19 15
Group 4 22 15 7
Total 266 (100%) 170 (63.9%)
96 
(36.1%)
NB: Each group refers to different co-authors 
responsible for data collection throughout 
Bangladesh
The stores were located throughout Bangladesh 
(Table 3 and Figure 1).
Table 3: Pharmacy/ Drug Store Location in 
Bangladesh 
Location No of Drugstore Visited
Rural Area Jessore District 25
Dhaka City South 48
Dhaka City North 21
Rural Area of Sylhet District 5
Rangpur City 5
Rural Area of Kushtia 20
Rural Area of Noagan 4
Comilla City 11
Chittagong  City 4
Rural Area of Comilla 12
Outskirts Dhaka 5
Bandarban  District Town 4
Bogra City 6
Total 170
NB: There are 64 districts in Bangladesh.
Figure 1: Location of Pharmacies and Drug Stores 
Taking Part in the Study. 
We will first report on changes in utilization patterns 
before reporting on price changes and shortages with 
the various medicines and PPE (Box 1).
3.1 Utilisation Patterns
Table 4 depicts changes in utilization patterns among 
pharmacies and drug stores between the beginning 
of March (first patients with COVID-19 identified) 
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until the end of May 2020. Encouragingly, there was 
no change in utilization patterns in just over half of 
the stores visited for antimalarial medicines (51.2%) 
despite global endorsements. However, there was 
increased utilization of antibiotics (70.6%), analgesics 
(97.6%), medicines for common colds (94.5%), and 
vitamins (90.6%), with some substantial increases 
seen (over 40% from baseline). Encouragingly, there 
was increased purchasing of PPE in over 95% of 
stores (Table 4). 
Antimalarials Antibiotics Analgesics
Common cold/ 
allergy
Vitamins/ immune 
boosters
Face masks/ 
thermometers
Hand sanitisers/ 
antiseptics
Data not available/ no demand 4 1
Decrease 5 5 1
No change 78 45 4 6 16 6 5
Increase (not specified) 72 104 140 99 140 139 100
Slight increase (not specified) 1 2
High increase (not specified) 7 14 2 3 10 1
5% - 20% increase 1 1
21 - 40% increase 1
41 - 60% increase 1 1 2
2 fold increase 6 7 1 8 7
2 - 3 fold increase 9 1 2 2
3 fold increase 1 1 6
3 to 4 fold increase
4 fold or greater increase 2
Total 170 170 170 110 170 170 110
No change/ no data/ decrease 51.2 29.4 2.4 5.5 9.4 4.7 4.5
Table 4: Utilisation Changes for Medicines and PPE Between Beginning March 2020 and End May 2020
3.2 Price Changes
Table 5 depicts changes in prices during the study 
period. As surmised, increases were seen in the 
prices of antimalarial tablets, some of which were 
substantial (over 50% from baseline). Encouragingly, 
there was no increase in prices/ no data available for 
antimalarial tablets among 50% of the stores visited 
during the study period, with a similar situation 
seen for antibiotics (65.3%), analgesics (54.7%), 
medicines for common cold/ allergies (68.2%) and 
vitamins (51.8%). However, there were typically 
increases in the prices of PPE (over 90% of stores), 
again with some substantial increases. 
NB: As mentioned – open-ended questions which depended on the willingness of the owners with no pre-set definitions
Table 5: Price Changes for Medicines, PPE and Hand Sanitisers between Beginning March 2020 and End 
May 2020
Antimalarials Antibiotics Analgesics
Common cold/ 
allergy
Vitamins/ immune 
boosters
Face masks/ 
thermometers
Hand sanitisers/ 
antiseptics
Data not available 4 1
No increase 81 111 93 75 88 7 8
Increase (not specified) 55 43 56 26 73 110 75
Slight increase (not specified) 1 1 2
High increase (not specified) 7 12 2 4
5% - 10% increase 1 1 2 1
11% - 20% increase 6 2 5 6 3
21 - 30% increase 4 3 1 2 2
31 - 40% increase 1 1 5
41 - 50% increase 7 1 5
51 - 60% increase 2 7
2 fold increase 5 5 5 19 3
2 - 3 fold increase 9 1 1 7
3 fold increase 7 1
3 to 4 fold increase 1
4 fold or greater increase 3
Total 170 170 170 110 170 170 110
% No change/ no data 50.0 65.3 54.7 68.2 51.8 4.7 7.3
NB: As mentioned – open-ended questions which depended on the willingness of the owners with no pre-set definitions
3.3 Shortages of Medicines and PPE
Perhaps not surprisingly, shortages of medicines and PPE was seen among the visited stores (Table 6). 
However, shortages appeared appreciably greater for PPE compared with targeted medicines, including 
antimalarials (54.1% of stores), antibiotics (17.6%), and analgesics (24.1%).
S 43
Bangladesh Journal of Medical Science, Vol : 19 Special Issue on Covid19, 2020
Table 6: Price Changes for Medicines, PPE and Hand Sanitisers between Beginning March 2020 and End 
May 2020
Antimalarials Antibiotics Analgesics
Common cold/ 
allergy
Vitamins/ immune 
boosters
Face masks/ 
thermometers
Hand sanitisers/ 
antiseptics
Adequate/ available/ normal/ no 
shortages 78 140 129 66 105 34 9
Limited shortages 1
Shortages 63 18 36 44 57 114 95
Limited availability 5
Shortages up to one month 1 2 8 10
Shortages 10 - 29% of the time 2 4 3 4
Shortages 30 - 39% of the time 2 2 1
Shortages 40 - 70% of the time 4 1
Shortages up to three months 1
Not available 20 2 1 8
Total 170 170 170 110 170 170 110
% Shortages 54.1 17.6 24.1 40.0 38.2 80.0 91.8
NB: As mentioned – open-ended questions which depended on the willingness of the owners with no pre-set definitions
3.4 Potential Ways Forward to Address 
Misinformation and Enhance Appropriate Use of 
Technologies 
Strategies to address misinformation and concerns 
are included in Table 7.
Table 7: Key activities among stakeholder groups 
to improve prevention and management of patients 
with COVID-19 
Stakeholder 
Group Suggested Activities
Government
•	 Encourage an evidence-based environment 
for key pronouncements, especially when 
proposing activities to prevent and treat 
COVID-19. This is especially important 
among lower-income families where monies 
spent on prevention and treatment will mean 
less monies for other medicines and food 
especially among patients with existing 
chronic NCDs and is in line with advice from 
the Council for International Organisations of 
Medical Sciences152
•	 Ensure active dissemination of activities to 
prevent the spread of COVID-19 including 
necessary sanitation and other measures 
mindful of the likely situation especially in 
densely populated towns 
•	 Continue to undertake planned programs 
to reduce AMR as well as improve the 
management of patients with chronic NCDs 
to reduce the unintended consequences of 
COVID-19. Similarly, for planned programs 
to reduce/ prevent malaria and tuberculosis
•	 Potentially seek to enhance local production 
of pharmaceuticals including active 
pharmaceutical ingredients (APIs) to reduce 
reliance on imports during pandemics
•	 Encourage greater diversity with the 
production of PPE building on the extensive 
garment-producing activities in Bangladesh
Stakeholder 
Group Suggested Activities
Physicians
•	 Ensure prescribed treatments are evidence-
based – especially among patients with 
limited resources
•	 Continue to encourage appropriate 
management of chronic NCDs given rising 
concerns
Pharmacists/ 
drug store 
owners
•	 Try to ensure that medicines or suitable 
alternatives, helpful for patients with 
COVID-19 are routinely available 
•	 Continue to encourage self-care/ hygiene 
measures including appropriate wearing of 
masks and hand sanitization
•	 In appropriate situations, continue to argue 
against the need for antibiotics where this 
is a concern, argue for good adherence 
to purchased medicines, and encourage 
appropriate referrals to other healthcare 
professionals were pertinent and possible
•	 Potentially seek novel approaches to help 
with adherence to medicines especially for 
patients with chronic diseases including 
messaging services given concerns with clinic 
availability 
•	 Potentially become involved in vaccination 
programs as studies suggest that when 
pharmacists provide immunizations, 
they substantially increase the number of 
vaccinated people135 
NB: NCDs = non-communicable diseases; PPE = personal 
protective equipment
4. Discussion
We believe this is the first comprehensive study 
worldwide to assess the impact of COVID-19 
on the utilization, availability, and price changes 
of medicines and PPE used to prevent and treat 
COVID-19 in LMICs such as Bangladesh with high 
patient co-payments and potentially catastrophic 
consequences for families when members become ill. 
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As expected, there was an increase in the utilization 
of suggested medicines and PPE worsened by 
lockdown and transportation restrictions as part of 
control strategies (Table 4). However, this was not 
as great for antimalarial treatments and antibiotics 
compared with analgesics and vitamins. As again 
expected, there were also price increases for pertinent 
medicines (Table 5), given some of the shortages 
seen (Table 6). This contrasts with the previous 
situation for antibiotics where Rahman et al. (2019) 
found only limited price increases between 2003 and 
201944. This is perhaps not unexpected given supply 
problems with importation during the pandemic and 
some of the increases in utilization seen soon after 
the start of the pandemic. Greater local production 
could help address this, especially with respect to 
PPE, which is similar to activities in other countries 
(Table 7)153. 
Table 6 discusses potential activities that can be 
undertaken among all key stakeholder groups 
in Bangladesh and wider to address issues and 
concerns. This also includes addressing unintended 
consequences of COVID-19, which we will be 
following up in the future.
Limitations with this study include the fact that we 
were unable to obtain exact details on changes in 
utilization and pricing patterns from all stores due 
to issues of confidentiality and lack of data to hand. 
We also did not cover all districts and regions in 
Bangladesh. However, we are confident our findings 
can be helpful for future planning, given the number 
of community pharmacies and drug stores involved. 
5. Conclusion
We have seen increases in utilization, prices, and 
shortages of pertinent medicines and equipment 
used to prevent and treat COVID-19. However, 
encouragingly shortages and price increases were 
not as great as originally expected. There are still 
issues of misinformation, especially regarding 
potential treatments Store owners, as well as other 
key stakeholder groups, can help address this in the 
future. 
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